In cancer research, the CBP and p300 proteins were known
as tumor suppressors until the Panne lab showed that several known cancer mutations could cause p300 to over-activate itself.
«Several studies and clinical evidence suggest AIM2 functions
as a
tumor suppressor, but
until now, we've had very little direct evidence to explains how this occurs,» said Justin E. Wilson, PhD, the study's first author and a postdoctoral fellow at UNC Lineberger, the UNC School of Medicine Department of Microbiology and Immunology and the Department of Genetics.